Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valeant Completes Sale of Sprout Pharmaceuticals Subsidiary | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Valeant Completes Sale of Sprout Pharmaceuticals Subsidiary

The divestiture was to former shareholders

By: Betsy Louda

, Contract Pharma

Valeant Pharmaceuticals announced that its affiliate has completed the sale of the Sprout Pharmaceuticals subsidiary (“Sprout”) to Sprout2. Sprout2 is affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of ADDYI (flibanserin) beginning in May 2019. In connection with the sale, Valeant has provided a $25 million loan to fund initial operating expenses.

 

In connection with the completion of the sale, Valeant has been released from the ongoing obligations of the original transaction to split future profits related to the sale of ADDYI with the former shareholders of Sprout, as well as certain related provisions, including the obligations to make certain marketing and other expenditures. Additionally, the parties to the existing litigation against the Company brought on behalf of the former shareholders of Sprout have filed a joint stipulation with the court that such claims be dismissed with prejudice.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters